Medpace Authorizes $1 Billion Buyback and Reports Higher Third-Quarter Profit
Medpace’s board approved a new $1 billion stock buyback authorization, effective through 2028, replacing an authorization with $527 million remaining. The company also reported higher third-quarter profit.
Medpace Holdings said its board approved a new stock repurchase authorization for 1 billion. The company also reported a rise in third-quarter profit. The authorization runs through 2028 and replaces the prior buyback program, which had 527 million remaining, Medpace said.